Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Influenza A virus vaccine H3N2 - Sanofi

Next Previous
Drug Profile

Influenza A virus vaccine H3N2 - Sanofi

Alternative Names: H3N2v vaccine - Sanofi; Monovalent A/H3N2v A/Minnesota/11/2010 NYMC X-203 vaccine - Sanofi; Monovalent inactivated influenza H3N2 variant vaccine - Sanofi

Latest Information Update: 04 Apr 2022

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator sanofi pasteur
  • Developer National Institute of Allergy and Infectious Diseases; Sanofi
  • Class Influenza A vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Influenza A virus H3N2 subtype

Most Recent Events

  • 23 Mar 2017 Phase-II development for Influenza-A virus H3N2 subtype (Prevention) is ongoing in USA (IM)
  • 29 Sep 2016 National Institute of Allergy and Infectious Diseases plans a phase II trial for Influenza-A virus H3N2 subtype (Prevention, In adults) in USA (IM) (NCT02921997)
  • 21 May 2014 NIAID plans a phase II trial for Influenza-A virus H3N2 subtype (prevention in infants, children and adolescents) in USA (NCT02100436)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top